Archives

img-01

India’s Medical Device Regulations: A 2025 Update

Over the past year, India has enacted a series of significant regulatory reforms aimed at boosting the safety, quality, and transparency of its medical device sector. The new regulations and amendments, covering everything from risk-based quality control of imports to enhanced adverse... Read More

img-01

Quick Asia Drug Updates (August 2025)

Historically known for their strength in generic drug manufacturing, today, Indian pharma firms are increasing their in-licensing transactions with international drug innovators. Big Indian pharma firms such as Cipla, Sun Pharma, and Dr. Reddy’s are acquiring rights to new patented products in the oncology, diabetes, central... Read More

img-01

India Medical Device Update (August 2025)

On July 22, the Indian Department of Pharmaceuticals National Pharmaceutical Pricing Authority (NPPA) issued a Memorandum with respect to the maximum retail prices (MRP) for non-scheduled formulations for new drugs and medical devices.  Essentially, it states that the NPPA monitors prices, and... Read More

img-01

More Unannounced FDA Inspections in China and India

On May 6, 2025, the U.S. Food and Drug Administration (FDA) announced a substantial increase in unannounced inspections at foreign manufacturing facilities that manufacture medical products for U.S. import. This initiative is a result of a White House Executive Order directing agencies... Read More

img-01

Drug Master File (DMF) Systems in Asia

Introduction Quality, safety, and efficacy are of the utmost importance for drug products. A vital part in achieving this is having a Drug Master File (DMF). A DMF is a confidential submission to a health authority to provide detailed information about the... Read More

img-01

India Medical Device Regulatory Updates

The Central Drugs Standard Control Organisation (CDSCO) has released a draft list to revise the current risk-based medical device classification in India for neurological and cardiovascular medical devices. The CDSCO has invited industry stakeholders to respond to the draft by April 30,... Read More

img-01

India To Overhaul Cell and Gene Therapy Regulatory Approach

India is making remarkable strides to transform its regulatory approach to cell and gene therapies (CGT), recognizing that rapidly approving therapies involves engaging more industry stakeholders and approving applications more quickly. At the CAR-T Summit 2025 that took place mid-April in Mumbai, the Drugs Controller... Read More

img-01

AI’s Expanding Role in India’s Healthcare Sector

Artificial intelligence (AI) is revolutionizing India’s health sector, addressing age-old concerns such as the scarcity of medical professionals and the need for improved rural accessibility. Realizing the huge potential of AI, the government of India is heavily investing in integrating AI within... Read More

img-01

Quick Indian Regulatory Updates

The Health Ministry of India has initiated an expert panel to monitor and address medical device adverse events to help promote patient safety. The panel will comprise experts from various disciplines of medicine, such as cardiology, neurology, and radiology. These experts will analyze and advise on needed actions to be... Read More